BOSTON

波士顿

,

，

May 21, 2026

2026年5月21日

/PRNewswire/ --

/PRNewswire/ --

Outcomes4Me Inc

Outcomes4Me Inc

., the leading direct-to-patient health technology company leveraging AI to revolutionize cancer care, today announced it has completed its acquisitions of two innovative platforms: Geno.Me, a platform that bridges the gap between patient data and researchers, and Realyze Intelligence, an AI clinical trial matching platform integrated into clinical workflows, initially developed at UPMC..

., 一家领先的直接面向患者的健康技术公司，利用人工智能革新癌症护理，今天宣布已完成对两个创新平台的收购：Geno.Me，一个弥合患者数据与研究人员之间差距的平台，以及Realyze Intelligence，一个最初在UPMC开发的集成到临床工作流程中的人工智能临床试验匹配平台。

These technologies, combined with Outcomes4Me's existing patient empowerment capabilities, will further support the company's work to help patients with cancer gain access to the latest, evidence-based and personalized treatment options and clinical trials. As the first direct-to-patient platform to integrate with the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), a relationship that dates to 2019, Outcomes4Me has demonstrated how putting patients at the center of their care decisions through access to the latest science-backed guidance, without fees or gatekeepers, improves the oncology patient experience..

这些技术与Outcomes4Me现有的患者赋能能力相结合，将进一步支持该公司帮助癌症患者获取最新、基于证据且个性化的治疗方案和临床试验的工作。作为首个直接面向患者并与NCCN肿瘤学临床实践指南（NCCN指南®）整合的平台（这一合作关系可以追溯到2019年），Outcomes4Me展示了如何通过免费提供最新的科学支持指导并将患者置于其治疗决策的中心，从而改善肿瘤患者体验，无需费用或中间人介入。

Through integrations with major electronic health record (EHR) systems including Epic, Cerner, and Meditech, Milwaukee-based Geno.Me allows patients to immediately access their health data and share it securely for research or other clinical purposes. Realyze Intelligence, which has been developed with input from several NCI-Accredited Cancer Centers, uses AI to abstract data from medical records into structured, oncology-specific clinical data models, which can identify relevant clinical trial cohorts in seconds.

通过与包括Epic、Cerner和Meditech在内的主要电子健康记录（EHR）系统集成，总部位于密尔沃基的Geno.Me使患者能够立即访问他们的健康数据，并安全地将其共享用于研究或其他临床目的。Realyze Intelligence是在多个NCI认证的癌症中心的参与下开发的，利用人工智能从医疗记录中提取数据，转化为结构化的、针对肿瘤学的临床数据模型，可以在几秒钟内识别相关的临床试验队列。

Realyze Intelligence's technology accelerates innovation, drives cost efficiencies, and helps patients pursue the latest treatment options..

Realyze Intelligence的技术加速创新，提高成本效益，并帮助患者追求最新的治疗选择。

Outcomes4Me also announced that Scot Stevens, Chief Information Officer at UPMC Hillman Cancer Center, has joined the company as a Strategic Advisor. Stevens brings expertise in health information technology and cancer care delivery, and his firsthand experience working closely with Realyze Intelligence in its early stages positions him as a uniquely valuable voice as Outcomes4Me integrates the platform into its broader patient-facing ecosystem..

Outcomes4Me 还宣布，UPMC Hillman 癌症中心的首席信息官 Scot Stevens 已加入该公司，担任战略顾问。Stevens 在健康信息技术和癌症护理交付方面具有专业知识，而且他早期与 Realyze Intelligence 密切合作的第一手经验，使他在 Outcomes4Me 将该平台整合到其更广泛的面向患者的生态系统时成为一个独具价值的声音。

'The intersection of clinical research and direct patient care has long been both a technological priority and a challenge, I am optimistic that AI-powered clinical trial matching can close the gap between patients and potentially life-changing research opportunities,' said Scot Stevens, CIO of UPMC Hillman Cancer Center and Strategic Advisor to Outcomes4Me.

“临床研究与直接患者护理的结合长期以来既是技术上的优先事项，也是挑战。我乐观地认为，人工智能驱动的临床试验匹配可以缩小患者与可能改变生命的科研机会之间的差距，”UPMC希尔曼癌症中心首席信息官兼Outcomes4Me战略顾问Scot Stevens表示。

'We have long focused on getting the right patients into the right clinical trials faster, at scale.'.

“我们长期以来一直专注于更快地将合适的患者纳入合适的临床试验，并且大规模地进行。”

'Together, Geno.Me and Realyze Intelligence's unique ability to enable immediate medical records access and abstraction that aligns with our structured clinical data models, along with rapid clinical trial matching, supercharges our ability to support patients living with cancer,' said Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me.

“通过结合Geno.Me和Realyze Intelligence的独特能力，我们能够立即获取和提取符合我们结构化临床数据模型的医疗记录，并快速匹配临床试验，这大大增强了我们为癌症患者提供支持的能力，”Outcomes4Me创始人兼首席执行官Maya R. Said博士说道。

'It also deepens our ability to help our commercial partners with both clinical trial recruitment and better understanding the patient experience through access to real-world evidence. By merging these technologies with our own, and welcoming Scot Stevens as a Strategic Advisor, we are building upon a foundation we've spent years establishing, putting more than 400,000 cancer patients at the center of their own care, armed with the same evidence and guidance their oncologists rely on, and now the most sophisticated AI-powered clinical trial matching available anywhere.'.

“它还加深了我们帮助商业伙伴进行临床试验招募的能力，并通过获取真实世界证据更好地理解患者体验。通过将这些技术与我们的技术相融合，并欢迎斯科特·史蒂文斯成为我们的战略顾问，我们正在建立一个经过多年打造的基础，将超过40万名癌症患者置于自身护理的中心，他们将获得与其肿瘤医生所依赖的相同证据和指导，以及现在全球最先进的AI驱动临床试验匹配。”

'I started Geno.Me because I recognized the lack of diversity and representation in clinical research,' said Britt Gottschalk, Founder of Geno.Me. 'I believe all patients deserve immediate access to their own data and should choose how that data is securely utilized. Now, Outcomes4Me's rich community of hundreds of thousands of patients can benefit from Geno.Me's powerful platform to support both their own health and treatment, while also contributing to important research in oncology.'.

“我创立Geno.Me是因为我认识到临床研究中缺乏多样性和代表性，”Geno.Me创始人布里特·戈特沙尔克说道。“我相信所有患者都应该立即获取自己的数据，并有权选择这些数据如何被安全使用。现在，Outcomes4Me拥有数十万患者的丰富社区可以受益于Geno.Me的强大平台，这不仅支持他们自身的健康和治疗，还为肿瘤学的重要研究做出贡献。”

'Realyze Intelligence was created to address one of the most significant gaps in clinical research: patients are often unaware of relevant clinical trial opportunities, while trial sponsors struggle to identify patient populations that meet increasingly complex inclusion and exclusion criteria. We have fundamentally reimagined clinical trial matching at scale by embedding it directly into clinical workflows in a way that accelerates research, reduces costs, and improves patient outcomes,' said Gilan El Saadawi, MD, PhD, Co-founder of Realyze Intelligence.

“Realyze Intelligence 的创立旨在解决临床研究中一个最重要的缺口：患者通常不了解相关的临床试验机会，而试验赞助方则难以找到符合日益复杂纳入和排除标准的患者群体。我们通过将大规模临床试验匹配直接嵌入临床工作流程，从根本上重新构想了这一过程，从而加速研究、降低成本并改善患者结果。” Realyze Intelligence 联合创始人吉兰·埃尔萨德维医学博士表示。

'The combination of Realyze's AI-powered clinical trial matching capabilities with a trusted, consumer-focused platform like Outcomes4Me, already relied upon by patients navigating their diagnoses and exploring treatment options, has the potential to be truly transformative for the future of precision medicine and patient access to care.'.

“将Realyze的AI驱动的临床试验匹配能力与像Outcomes4Me这样受信赖的、以消费者为中心的平台相结合，该平台已经被患者用于诊断导航和探索治疗选择，这对精准医疗的未来以及患者获得护理的机会而言，具有真正的变革潜力。”

With these acquisitions and the addition of Scot Stevens as Strategic Advisor, Outcomes4Me is building the most comprehensive direct-to-patient cancer care platform in the world, one that gives every patient access to the same cutting-edge guidance, clinical trials, and personalized support once available only to the few..

通过这些收购以及Scot Stevens作为战略顾问的加入，Outcomes4Me正在构建全球最全面的直接面向患者的癌症护理平台，该平台让每位患者都能获得曾经仅少数人可享的前沿指导、临床试验和个性化支持。

About Outcomes4Me

关于Outcomes4Me

Named to TIME's Best Inventions of 2025 and recognized as a Fast Company World Changing Idea, Outcomes4Me is the leading direct-to-patient platform for cancer care, supporting more than 400,000 patients from diagnosis through every stage of treatment. Its AI-driven platform integrates clinical guidelines, genomics, clinical trial matching, and symptom tracking to help patients make informed, confident decisions about their care, without fees or gatekeepers.

被评为《时代》杂志2025年最佳发明之一，并被《快公司》评为改变世界的理念，Outcomes4Me 是领先的直接面向患者的癌症护理平台，支持超过40万名患者从诊断到每个治疗阶段。其人工智能驱动的平台整合了临床指南、基因组学、临床试验匹配和症状追踪，帮助患者在无需费用或中间人的情况下做出明智且自信的护理决策。

With 7 of the top 10 oncology pharmaceutical companies as customers, Outcomes4Me generates unique, at-scale proprietary datasets and insights that accelerate innovation in cancer care, helping bring better treatments to more patients, faster. For more information, visit .

拥有排名前十的肿瘤学制药公司中的7家作为客户，Outcomes4Me生成独特的大规模专有数据集和见解，加速了癌症治疗的创新，帮助更快地为更多患者带来更好的治疗。欲了解更多信息，请访问。

www.outcomes4me.com

www.outcomes4me.com

.

。

SOURCE Outcomes4Me Inc.

来源：Outcomes4Me Inc.

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示